Non-Alcoholic Fatty Liver DiseaseSymptoms, Doctors, Treatments, Advances & More
Non-Alcoholic Fatty Liver Disease Overview
Learn About Non-Alcoholic Fatty Liver Disease
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Banner - University Medicine Transplant Institute
I love running, traveling to the new places, and watching sports. Dr. Wijarnpreecha is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Cirrhosis, Malabsorption, Liver Transplant, and Kidney Transplant. Dr. Wijarnpreecha is board certified in American Board Of Internal Medicine/Gastroenterology, American Board Of Internal Medicine, and American Board Of Internal Medicine/Transplant Hepatology. Dr. Wijarnpreecha is currently accepting new patients.
Northwell Health Physician Partners Sandra Atlas Bass Center For Liver Diseases
Dr. Sanjaya K. Satapathy is the medical director of the Center for Liver Disease and Transplantation at the Northwell Transplant Institute, program director of Northwell's Transplant Hepatology Fellowship, and professor of medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.His path to medicine began in India, where he was inspired by his father an engineer with a passion for homeopathy to pursue a career in healthcare. He earned his medical degree from Veer Surendra Sai Medical College, followed by fellowship training in gastroenterology and hepatology in the early 2000s. During that time, he witnessed the profound need for liver transplantation in India, where access remained scarce.While presenting his research at a conference in the United States, Dr. Satapathy was drawn to the opportunities and possibilities for advancing transplantation in America. He decided to continue his career in the United States, completing additional residency and fellowship training before serving as a transplant hepatologist in Memphis. In 2019, he was recruited to Northwell.It was a dream to begin from zero and build a transplant program that could be a model not just for the area or the state, but for the country, says Dr. Satapathy. Within only a few years, we've been able to achieve that goal, because Northwell has all the elements and resources to be one of the best programs in the nation. The expertise we have is unparalleled, with a collaborative team that encompasses all levels of care.The program was founded just in time for a huge surge in demand for liver transplants in the area, he adds. Liver disease and other liver issues are on the rise, making the need for an extensive program crucial for those in the New York region. Part of the program's strength is innovation. For example, Northwell is utilizing an approach that allows donated organs to be safely preserved for a longer period of time, which means needed organs can travel longer distances even from as far away as Hawaii. Northwell is also running several clinical trials on transplant medications and operates a robust transplant hepatology fellowship program to train the next generation of doctors a program Dr. Satapathy launched.I'm passionate about this work, and particularly about my patients, he says. I see every patient as my family, and my focus is on what I can do next to help them. Dr. Satapathy is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Spontaneous Bacterial Peritonitis, Non-Alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis (NASH), Liver Transplant, and Endoscopy. Dr. Satapathy is board certified in American Board Of Internal Medicine, American Board Of Internal Medicine/Gastroenterology, and American Board Of Internal Medicine/Transplant Hepatology.
Duke Liver/Intestine Transplant Clinic - Clinic 2B/2C
I care for patients with liver disease, particularly those suffering from complications of cirrhosis from fatty liver disease and liver cancer. Dr. Ann Moylan is rated as an Elite provider by MediFind in the treatment of Non-Alcoholic Fatty Liver Disease. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Non-Alcoholic Fatty Liver Disease, Cirrhosis, Nonalcoholic Steatohepatitis (NASH), Liver Cancer, and Liver Transplant. Dr. Ann Moylan is board certified in American Board Of Internal Med, Gastroenterology and American Board Of Internal Med, Transplant Hepatology.
Summary: The purpose of this study is to assess the safety and efficacy of efimosfermin alfa in the resolution of steatohepatitis and improvement of liver-related clinical outcome compared to placebo in individuals with MASH and biopsy-confirmed F2- or F3-stage fibrosis.
Summary: This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in thi...


